Stay updated with breaking news from Immune Modulation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- OncoPep, Inc., a developer of transformative immunotherapeutics, announced $11 million in Series D funding. The Series D was led by Tera...
/PRNewswire/ -- OncoPep, Inc., a developer of transformative immunotherapeutics, announced $11 million in Series D funding. The Series D was led by Tera...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
with strong interpersonal communication skills to join the talented Cancer Immunology & Immune Modulation (CI & IM) Research Group at Boehringer Ingelheim’s US research facility in Ridgefield, CT. The successful candidate will work within the CI&IM in vivo pharmacology group to advance both exploratory and drug candidate discovery programs and provide target discovery/validation, in-vivo efficacy, mechanism of action (MOA) and pharmacodynamic data essential to drive projects into clinical development. The ideal candidate will collaborate with other members of in vivo teams and with ...